Developer docs
API playgroundTry for free, no card

Search company profiles

RefinedScience

Full company profile

uuid000kld6

Namestring
RefinedScience
Legal namestring
RefinedScience
Company typeenum
Private
Founded yearint
2024
Descriptiontext

RefinedScience is a precision oncology company that operates a single-cell multi-omics platform combining longitudinal clinical data, biobank samples, and EHR records with AI-powered analysis tools to support pharmaceutical drug development. The company is structured as a joint venture between the University of Colorado Anschutz Medical Campus and UCHealth, headquartered in Aurora, Colorado, and was formally established in 2024. Its proprietary technology stack centers on a 41TB single-cell database covering 300+ AML patients with CITE-seq surface protein mapping and single-cell transcriptomics, alongside four named AI tools (scExploreR, Marksman, Scout, PULSE), 700+ functional assays, and 12 standardized protocols. RefinedScience positions itself as a biology-first partner to pharma rather than a pure software vendor, emphasizing that single-cell resolution of clinically annotated human tissue addresses the 25% Phase II success rate problem in oncology.

RefinedScience generates revenue primarily through professional services engagements with pharmaceutical and biotechnology partners, plus co-development/licensing partnerships in ADC discovery. Its service offering is segmented across Discovery (target identification, validation, patient stratification), Translational Validation (resistance profiling, rational combinations, preclinical development), and Clinical Development (patient stratification, biomarker analysis, external dataset comparison, synthetic trial simulation, CDx discovery). The ADC Discovery Program in AML is a distinct offering that uses the platform to identify and validate novel ADC targets for co-development with partners. Pricing is custom and not publicly disclosed, and all engagements are shaped around specific biology problems rather than a fixed service catalog. Named customers and partners include OncoVerity (Phase II cusatuzumab AML support), an unnamed Global Pharmaceutical Company and Large Pharma for AML profiling and biomarker work, and ImCheck Therapeutics (work supporting FDA Breakthrough Therapy Designation and contributing to Ipsen's €1B acquisition of ImCheck, with a follow-on engagement with Ipsen).

Go-to-market is exclusively direct enterprise B2B: no self-serve, marketplace, or e-commerce channels. The company engages prospects through industry conferences (AACR), LinkedIn, website content, and direct outreach via Partnerships@refinedscience.com. Distribution was extended in October 2025 through a multi-year strategic collaboration with Verily (Alphabet), UCHealth, and CU Anschutz, which placed RefinedScience's longitudinal AML dataset on the Verily Exchange and validated 95%+ accuracy and 30x faster data extraction benchmarks using Verily Refinery. The company also spun out OncoVerity as a clinical-stage vehicle to advance the cusatuzumab Phase II program, with RefinedScience providing translational and clinical operations support.

Short descriptiontext

RefinedScience is a precision oncology joint venture between CU Anschutz and UCHealth that combines a 41TB single-cell database with proprietary AI tools to provide biology-first drug development services to pharmaceutical partners across target validation, translational research, and clinical execution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAurora, United States
HQ citystring
Aurora
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology services, single-cell multi-omics, pharma R&D services, ADC discovery, clinical data analytics
Industry5 codes
PRIMARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Precision Oncology Drug Development Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharma R&D Services
TypeProfessional Services
Description

Biology-first drug development support services provided to pharmaceutical partners across discovery, translational validation, and clinical development stages. Engagements are shaped around specific biology problems and include target validation, patient stratification, and clinical trial design support.

refinedscience.com:443
2ADC Discovery Partnerships
TypeLicensing Royalties
Description

Co-development partnerships for ADC (antibody-drug conjugate) target discovery in AML. Seeking partners with ADC platforms, antibody engineering, or clinical infrastructure to co-develop programs toward lead candidates.

refinedscience.com:443
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

RefinedScience provides biology-first precision oncology drug development services to pharmaceutical partners, combining a 41TB single-cell database (300+ AML patients) with proprietary AI tools (scExploreR, Marksman, Scout, PULSE) and 700+ functional assays. The company engages pharma partners from target identification through clinical execution, offering custom solutions including ADC target discovery in AML, patient stratification, and clinical trial design support across seven oncology indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Greater than 95% accuracy on complex variables like karyotype strings and NGS mutations
+5 more records
Product overview1 text field

RefinedScience is a biology-first precision oncology company offering an integrated platform combining four core capabilities: Deep Clinical & Multimodal Data (unified access to longitudinal patient data, biobank samples, and EHR data across 7 oncology indications), AI-Powered Analysis (proprietary tools including scExploreR, Marksman, Scout, and PULSE supporting 1,000+ AI-generated reports), Biological Validation (700+ functional assays including drug testing on primary patient tissue and patient-derived organoids), and Expert Multidisciplinary Team expertise. The platform supports pharma partners through Pharma R&D Services spanning Discovery, Translational Validation, and Clinical Development phases, as well as a dedicated ADC Discovery Program for AML. A longitudinal AML dataset with 300+ patients is available via the Verily Exchange partnership. The company operates as a joint venture between CU Anschutz and UCHealth, with a spinout company OncoVerity advancing Phase II clinical programs.

Product and service3 records
1Pharma R&D Services
CategoryDrug Development Services
Description

Integrated drug development support services for pharmaceutical partners across the full development lifecycle from target identification through clinical execution. Services include Discovery (target identification, validation, patient stratification), Translational Validation (resistance mechanism profiling, rational combination identification, preclinical development), and Clinical Development (patient stratification, biomarker analysis, external dataset comparison, synthetic trial simulation, CDx discovery).

2ADC Discovery Program
CategoryDrug Discovery Services
Description

A systematic ADC target discovery program for acute myeloid leukemia (AML) utilizing the 41TB single-cell database, tumor-initiating cell models, CITE-seq surface antigen mapping, and functional primary tissue validation to identify and validate novel ADC targets. Offered as co-development partnerships with ADC platform companies, antibody engineering firms, and clinical infrastructure partners.

3RefinedScience Longitudinal AML Dataset
CategoryData Product
Description

A longitudinal Acute Myeloid Leukemia dataset covering 300+ venetoclax and azacitidine-treated patients with clinical and CITE-seq data, made available on the Verily Exchange platform as a specialized research dataset for precision health AI applications.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-01
Description

Multi-year strategic collaboration announced October 2025 between Verily, UCHealth, CU Anschutz, and RefinedScience to create AI-ready biomedical data pipelines and develop novel AI/ML models. Initial collaboration demonstrated 95%+ accuracy and 30x faster data extraction from AML patient records. RefinedScience longitudinal AML dataset (300+ patients) available on Verily Exchange.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture partner providing institutional access to academic research capabilities, clinical data infrastructure, and world-class AML and ADC advisors. CU Anschutz has committed to multi-year expansion scaling data solutions to population-level datasets across cardiovascular disease, neuroscience, and ophthalmology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture partner providing longitudinal patient data, biobank samples, and EHR data access across 7 oncology indications. Unified access to clinical infrastructure enables patient-linked single-cell datasets that external vendors cannot replicate.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spinout company with RefinedScience providing end-to-end clinical trial support. OncoVerity CEO Max Calao and CMO Mike Boyiadzis lead the Phase II cusatuzumab program supported by RefinedScience's translational and clinical operations capabilities.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Following Ipsen's €1B acquisition of ImCheck Therapeutics, RefinedScience maintains a follow-on engagement with Ipsen in ADC development. RefinedScience work on ImCheck's Phase I program contributed to FDA Breakthrough Therapy Designation and was included in acquisition rationale.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Supported ImCheck's Phase I program through real-world external dataset comparison and propensity-matched analysis. Work was included in FDA Breakthrough Therapy Designation application and contributed to biological credibility supporting company's acquisition by Ipsen.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading provider of single-cell sequencing and multi-omics technologies (Chromium, Visium, Xenium). Directly comparable to RefinedScience on the single-cell technology foundation underlying the company's CITE-seq and transcriptomics platform.

2Tempus AI
TypeBroad incumbent
Description

Precision medicine data platform combining clinical data, molecular profiling, and AI to support both patient care and biopharma drug development. Operates at much greater scale than RefinedScience across many indications, with overlapping value proposition of integrating clinical and molecular data for pharma partners.

TypeBroad incumbent
Description

Subsidiary of Roche providing comprehensive genomic profiling for oncology patients and biopharma partners. Comparable in delivering molecular profiling plus biopharma services in oncology, though at significantly larger scale and broader indication coverage.

TypeEmerging player
Description

AI-driven drug discovery company combining high-throughput biology and machine learning for precision drug development. Comparable in using proprietary data and AI tooling to improve target identification and clinical translation, though focused on building an internal pipeline rather than pharma services.

TypeDirect peer
Description

Molecular profiling and AI company integrating multi-omics, AI, and clinical data to support biopharma drug development and patient care in oncology. Closely comparable business model of monetizing proprietary molecular+clinical datasets through pharma services and ADC/biomarker partnerships.

TypeDirect peer
Description

Genomic profiling company with biopharma services business in oncology, including tumor profiling and MRD detection. Comparable in serving pharma partners with molecular data products and analytical services to support clinical development, particularly in oncology.

TypeDirect peer
Description

Immune profiling company combining sequencing and AI for drug discovery and clinical development support. Comparable in offering proprietary biological data assets plus pharma R&D services, particularly in immune-mediated and hematologic indications.

TypeEmerging player
Description

Computational drug discovery platform combining physics-based simulation and AI for pharma R&D. Comparable in the AI-enabled drug development category, though RefinedScience's biology-first approach with patient-linked tissue data is a meaningful differentiation.

TypeEmerging player
Description

AI-driven precision medicine drug discovery company combining patient data, AI, and automated lab capabilities. Comparable in merging biology data with AI to enable precision drug development, particularly in oncology.

TypeOthers
Description

Alphabet's precision health technology company and RefinedScience's strategic partner. Operates in adjacent precision health AI space and is also a distribution partner via Verily Exchange, making it both an enabler and a potential competitor in AI-ready biomedical data infrastructure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

RefinedScience

Precision Oncology Drug Development Servicesrefinedscience.com

RefinedScience is a precision oncology joint venture between CU Anschutz and UCHealth that combines a 41TB single-cell database with proprietary AI tools to provide biology-first drug development services to pharmaceutical partners across target validation, translational research, and clinical execution.

What RefinedScience does

RefinedScience is a precision oncology company that operates a single-cell multi-omics platform combining longitudinal clinical data, biobank samples, and EHR records with AI-powered analysis tools to support pharmaceutical drug development. The company is structured as a joint venture between the University of Colorado Anschutz Medical Campus and UCHealth, headquartered in Aurora, Colorado, and was formally established in 2024. Its proprietary technology stack centers on a 41TB single-cell database covering 300+ AML patients with CITE-seq surface protein mapping and single-cell transcriptomics, alongside four named AI tools (scExploreR, Marksman, Scout, PULSE), 700+ functional assays, and 12 standardized protocols. RefinedScience positions itself as a biology-first partner to pharma rather than a pure software vendor, emphasizing that single-cell resolution of clinically annotated human tissue addresses the 25% Phase II success rate problem in oncology.

RefinedScience generates revenue primarily through professional services engagements with pharmaceutical and biotechnology partners, plus co-development/licensing partnerships in ADC discovery. Its service offering is segmented across Discovery (target identification, validation, patient stratification), Translational Validation (resistance profiling, rational combinations, preclinical development), and Clinical Development (patient stratification, biomarker analysis, external dataset comparison, synthetic trial simulation, CDx discovery). The ADC Discovery Program in AML is a distinct offering that uses the platform to identify and validate novel ADC targets for co-development with partners. Pricing is custom and not publicly disclosed, and all engagements are shaped around specific biology problems rather than a fixed service catalog. Named customers and partners include OncoVerity (Phase II cusatuzumab AML support), an unnamed Global Pharmaceutical Company and Large Pharma for AML profiling and biomarker work, and ImCheck Therapeutics (work supporting FDA Breakthrough Therapy Designation and contributing to Ipsen's €1B acquisition of ImCheck, with a follow-on engagement with Ipsen).

Go-to-market is exclusively direct enterprise B2B: no self-serve, marketplace, or e-commerce channels. The company engages prospects through industry conferences (AACR), LinkedIn, website content, and direct outreach via Partnerships@refinedscience.com. Distribution was extended in October 2025 through a multi-year strategic collaboration with Verily (Alphabet), UCHealth, and CU Anschutz, which placed RefinedScience's longitudinal AML dataset on the Verily Exchange and validated 95%+ accuracy and 30x faster data extraction benchmarks using Verily Refinery. The company also spun out OncoVerity as a clinical-stage vehicle to advance the cusatuzumab Phase II program, with RefinedScience providing translational and clinical operations support.

RefinedScience firmographics

Firmographics
Name
RefinedScience
Legal name
RefinedScience
Website
https://refinedscience.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
RefinedScience is a precision oncology joint venture between CU Anschutz and UCHealth that combines a 41TB single-cell database with proprietary AI tools to provide biology-first drug development services to pharmaceutical partners across target validation, translational research, and clinical execution.
Ownership category
akta.pro rank

RefinedScience industry classification

Industry
Product category
Precision Oncology Drug Development Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAE
Clinical Decision Support & Workflow Integration (EHR/oncology systems)
SECONDARYHLAAANAI
Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGACAE
Clinical Trial Site Operations & Study Coordination

Keywords

  • Precision oncology services
  • Single-cell multi-omics
  • Pharma R&D services
  • ADC discovery
  • Clinical data analytics

Where RefinedScience is headquartered

Location

Headquarters

HQ city
Aurora
HQ country
United States
HQ region
North America

Offices1 record

Markets served

RefinedScience business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Pharma R&D Services: Biology-first drug development support services provided to pharmaceutical partners across discovery, translational validation, and clinical development stages. Engagements are shaped around specific biology problems and include target validation, patient stratification, and clinical trial design support.
  2. ADC Discovery Partnerships: Co-development partnerships for ADC (antibody-drug conjugate) target discovery in AML. Seeking partners with ADC platforms, antibody engineering, or clinical infrastructure to co-develop programs toward lead candidates.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

RefinedScience product offering

Product offering

Core offering

RefinedScience provides biology-first precision oncology drug development services to pharmaceutical partners, combining a 41TB single-cell database (300+ AML patients) with proprietary AI tools (scExploreR, Marksman, Scout, PULSE) and 700+ functional assays. The company engages pharma partners from target identification through clinical execution, offering custom solutions including ADC target discovery in AML, patient stratification, and clinical trial design support across seven oncology indications.

Product overview

RefinedScience is a biology-first precision oncology company offering an integrated platform combining four core capabilities: Deep Clinical & Multimodal Data (unified access to longitudinal patient data, biobank samples, and EHR data across 7 oncology indications), AI-Powered Analysis (proprietary tools including scExploreR, Marksman, Scout, and PULSE supporting 1,000+ AI-generated reports), Biological Validation (700+ functional assays including drug testing on primary patient tissue and patient-derived organoids), and Expert Multidisciplinary Team expertise. The platform supports pharma partners through Pharma R&D Services spanning Discovery, Translational Validation, and Clinical Development phases, as well as a dedicated ADC Discovery Program for AML. A longitudinal AML dataset with 300+ patients is available via the Verily Exchange partnership. The company operates as a joint venture between CU Anschutz and UCHealth, with a spinout company OncoVerity advancing Phase II clinical programs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharma R&D Services Integrated drug development support services for pharmaceutical partners across the full development lifecycle from target identification through clinical execution. Services include Discovery (target identification, validation, patient stratification), Translational Validation (resistance mechanism profiling, rational combination identification, preclinical development), and Clinical Development (patient stratification, biomarker analysis, external dataset comparison, synthetic trial simulation, CDx discovery).
  • ADC Discovery Program A systematic ADC target discovery program for acute myeloid leukemia (AML) utilizing the 41TB single-cell database, tumor-initiating cell models, CITE-seq surface antigen mapping, and functional primary tissue validation to identify and validate novel ADC targets. Offered as co-development partnerships with ADC platform companies, antibody engineering firms, and clinical infrastructure partners.
  • RefinedScience Longitudinal AML Dataset A longitudinal Acute Myeloid Leukemia dataset covering 300+ venetoclax and azacitidine-treated patients with clinical and CITE-seq data, made available on the Verily Exchange platform as a specialized research dataset for precision health AI applications.

Quantifiable outcome

  • Greater than 95% accuracy on complex variables like karyotype strings and NGS mutations
  • +5 more outcomes

Companies that use RefinedScience

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

RefinedScience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

RefinedScience partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Verily (Alphabet)coreStrategic or Co-development Partner · 1 October 2025Multi-year strategic collaboration announced October 2025 between Verily, UCHealth, CU Anschutz, and RefinedScience to create AI-ready biomedical data pipelines and develop novel AI/ML models. Initial collaboration demonstrated 95%+ accuracy and 30x faster data extraction from AML patient records. RefinedScience longitudinal AML dataset (300+ patients) available on Verily Exchange.
  • CU Anschutz (University of Colorado Anschutz Medical Campus)coreStrategic or Co-development PartnerJoint venture partner providing institutional access to academic research capabilities, clinical data infrastructure, and world-class AML and ADC advisors. CU Anschutz has committed to multi-year expansion scaling data solutions to population-level datasets across cardiovascular disease, neuroscience, and ophthalmology.
  • UCHealthcoreStrategic or Co-development PartnerJoint venture partner providing longitudinal patient data, biobank samples, and EHR data access across 7 oncology indications. Unified access to clinical infrastructure enables patient-linked single-cell datasets that external vendors cannot replicate.
  • OncoVeritycoreStrategic or Co-development PartnerSpinout company with RefinedScience providing end-to-end clinical trial support. OncoVerity CEO Max Calao and CMO Mike Boyiadzis lead the Phase II cusatuzumab program supported by RefinedScience's translational and clinical operations capabilities.
  • IpsenminorStrategic or Co-development PartnerFollowing Ipsen's €1B acquisition of ImCheck Therapeutics, RefinedScience maintains a follow-on engagement with Ipsen in ADC development. RefinedScience work on ImCheck's Phase I program contributed to FDA Breakthrough Therapy Designation and was included in acquisition rationale.
  • ImCheck TherapeuticsminorStrategic or Co-development PartnerSupported ImCheck's Phase I program through real-world external dataset comparison and propensity-matched analysis. Work was included in FDA Breakthrough Therapy Designation application and contributed to biological credibility supporting company's acquisition by Ipsen.

Scale indicators10 records

Recent moves5 records

Expansion highlights2 records

RefinedScience competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: Leading provider of single-cell sequencing and multi-omics technologies (Chromium, Visium, Xenium). Directly comparable to RefinedScience on the single-cell technology foundation underlying the company's CITE-seq and transcriptomics platform.
  • Caris Life Sciences: Molecular profiling and AI company integrating multi-omics, AI, and clinical data to support biopharma drug development and patient care in oncology. Closely comparable business model of monetizing proprietary molecular+clinical datasets through pharma services and ADC/biomarker partnerships.
  • Personalis: Genomic profiling company with biopharma services business in oncology, including tumor profiling and MRD detection. Comparable in serving pharma partners with molecular data products and analytical services to support clinical development, particularly in oncology.
  • Adaptive Biotechnologies: Immune profiling company combining sequencing and AI for drug discovery and clinical development support. Comparable in offering proprietary biological data assets plus pharma R&D services, particularly in immune-mediated and hematologic indications.

Broad incumbents

  • Tempus AI: Precision medicine data platform combining clinical data, molecular profiling, and AI to support both patient care and biopharma drug development. Operates at much greater scale than RefinedScience across many indications, with overlapping value proposition of integrating clinical and molecular data for pharma partners.
  • Foundation Medicine: Subsidiary of Roche providing comprehensive genomic profiling for oncology patients and biopharma partners. Comparable in delivering molecular profiling plus biopharma services in oncology, though at significantly larger scale and broader indication coverage.

Emerging players

  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology and machine learning for precision drug development. Comparable in using proprietary data and AI tooling to improve target identification and clinical translation, though focused on building an internal pipeline rather than pharma services.
  • Schrödinger: Computational drug discovery platform combining physics-based simulation and AI for pharma R&D. Comparable in the AI-enabled drug development category, though RefinedScience's biology-first approach with patient-linked tissue data is a meaningful differentiation.
  • Exscientia: AI-driven precision medicine drug discovery company combining patient data, AI, and automated lab capabilities. Comparable in merging biology data with AI to enable precision drug development, particularly in oncology.

Others

  • Verily: Alphabet's precision health technology company and RefinedScience's strategic partner. Operates in adjacent precision health AI space and is also a distribution partner via Verily Exchange, making it both an enabler and a potential competitor in AI-ready biomedical data infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

RefinedScience social profiles

Digital presence

RefinedScience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

RefinedScience leadership team

Management profile

Number of profiles

Profiles10 records

RefinedScience funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

RefinedScience M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about RefinedScience

What does RefinedScience do?

RefinedScience provides biology-first precision oncology drug development services to pharmaceutical partners, combining a 41TB single-cell database (300+ AML patients) with proprietary AI tools (scExploreR, Marksman, Scout, PULSE) and 700+ functional assays. The company engages pharma partners from target identification through clinical execution, offering custom solutions including ADC target discovery in AML, patient stratification, and clinical trial design support across seven oncology indications.

Is RefinedScience a public or private company?

RefinedScience is a private company. It is classified as corporate owned and is currently operating.

When was RefinedScience founded?

RefinedScience was founded in 2024. It employs 11 to 50 people.

Where is RefinedScience based?

RefinedScience is headquartered in Aurora, United States, in the North America region.

How does RefinedScience make money?

Two revenue lines are on record. Pharma R&D Services are the primary driver. The others are ADC Discovery Partnerships.

Who are RefinedScience's main competitors?

Direct peers on record are 10x Genomics, Caris Life Sciences, Personalis and Adaptive Biotechnologies. Broad incumbents are Tempus AI and Foundation Medicine. Emerging players are Recursion Pharmaceuticals, Schrödinger and Exscientia. Verily is listed as an others.

Does RefinedScience have an API?

No public API is recorded for RefinedScience.

What industry is RefinedScience in?

RefinedScience's product category is Precision Oncology Drug Development Services. Its primary akta.pro industry code is HLAAANAE, Clinical Decision Support & Workflow Integration (EHR/oncology systems), with a secondary code of HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogRefinedScience Expands Deep, Multimodal Pancreatic Cancer DatasetRefinedScience announced a multi-institutional agreement to expand the Marsico Pancreatic Cancer Initiative into the world's largest multimodal single-cell pancreatic cancer dataset by 2026, with access to over 2,000 consented samples. The dataset combines single-cell sequencing, genomic profiling, and spatial transcriptomics with clinical data. The initiative includes a new collaboration with Oregon Health & Science University.FinancialContent Business PageRefinedScience Expands Deep, Multimodal Pancreatic Cancer DatasetRefinedScience announced a multi-institutional agreement to expand the Marsico Pancreatic Cancer Initiative's dataset, aiming to become the world's largest multimodal single-cell pancreatic cancer dataset by 2026. The dataset will include over 2,000 consented samples from CU Anschutz, UCHealth, and OHSU, with single-cell and spatial profiles linked to clinical outcomes.Healthcare DiveHow AI is tackling one of the biggest bottlenecks in clinical research and beyondVerily Health, UCHealth, and RefinedScience piloted AI to abstract unstructured clinical data, achieving over 95% accuracy versus 72% for standard AI. The approach reduced manual abstraction from 1,200 to 40 hours, and identified a precision biomarker for AML patients.HIT ConsultantVerily Launches Self-Serve Access to Pre Platform with New Segmed and RefinedScience DatasetsAlphabet's Verily has launched a free, self-serve Standard tier for its Pre precision health platform, enabling researchers to instantly access its data catalog and trusted research environment using a Google account without traditional IT provisioning delays. The launch adds three specialized datasets to the platform: a longitudinal Acute Myeloid Leukemia dataset from RefinedScience covering over 300 patients, a real-world breast imaging database from Segmed with 558 digital breast tomosynthesis exams, and a CRISPR interference dataset from Transcripta Bio mapping gene knockdowns linked to rare diseases. Verily is applying a SaaS democratization strategy to clinical research, allowing researchers to spin up collaborative workspaces and bypass months of institutional red tape previously required to access datasets of this magnitude.VerilyThe 'unseen' value of precision dataVerily, UCHealth, University of Colorado Anschutz, and RefinedScience are collaborating to overcome low-resolution clinical data bottlenecks that prevent effective AI and machine learning applications in healthcare, using Verily Refinery to transform disparate data into structured, clinically informed formats. In a case study focused on acute myeloid leukemia, their approach achieved greater than 95% accuracy on complex variables like karyotype strings and NGS mutations while reducing researcher time by 97%, and identified cusatuzumab as a potential drug rescue opportunity for a specific AML patient subclass. Following positive results, CU Anschutz has committed to a multi-year expansion scaling the solution to population-level datasets across cardiovascular disease, neuroscience, and ophthalmology.Business Wire BlogVerily, UCHealth, University of Colorado Anschutz, and RefinedScience Launch Strategic Collaboration for AI-Powered Research and Care TransformationVerily announced a multi-year collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience to transform data use and care delivery using AI. The partnership will aggregate biomedical data and develop AI/ML models across therapeutic areas, with RefinedScience achieving over 95% accuracy in AI models for Acute Myeloid Leukemia. The collaboration aims to expand into additional data modalities and therapeutic areas.FinancialContent Business PageVerily, UCHealth, University of Colorado Anschutz, and RefinedScience Launch Strategic Collaboration for AI-Powered Research and Care TransformationVerily, UCHealth, the University of Colorado Anschutz, and RefinedScience announced a multi-year collaboration to use Verily's platform for AI-powered research and care transformation. The partnership will aggregate biomedical data and develop AI/ML models across therapeutic areas, with RefinedScience already achieving over 95% accuracy in AI models for Acute Myeloid Leukemia.PharmiWeb.comVerily, UCHealth, University of Colorado Anschutz, and RefinedScience Launch Strategic Collaboration for AI-Powered Research and Care TransformationVerily announced a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience to transform healthcare data usage and patient care delivery using AI and digital technology. The partnership will aggregate biomedical data on Verily's platform to develop AI/ML models across oncology, cardiovascular, neuroscience and other therapeutic areas, with initial results showing over 95% accuracy in Acute Myeloid Leukemia analysis and 30x faster data extraction. RefinedScience, a joint venture between CU Anschutz and UCHealth focused on drug discovery, will work with Verily to develop advanced analytical tools for complex biological data.